CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factorGuiqi Zhu, Ying–Hong Shi|Cell Discovery|2023Cited by 307
A RIPK3-independent role of MLKL in suppressing parthanatos promotes immune evasion in hepatocellular carcinomaXi‐Fei Jiang, Ying–Hong Shi|Cell Discovery|2023Cited by 50
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trialYing–Hong Shi, Enxiao Li, Tianfu Wen et al.|The Lancet. Gastroenterology & hepatology|2025Cited by 39
Metabolism archetype cancer cells induce protumor TREM2+ macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinomaTianhao Chu, Ying–Hong Shi|Nature Communications|2025Cited by 23